AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01912417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise with cycle ergometer during hemodialysis
Description: Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
Study NCT04145999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP application
Description: The study participant will receive topical anesthesia with lidocaine ointment (50mg/g). After 5 minutes the face will be cleaned with 0.5% alcohol chlorhexidine solution. The newly obtained platelet-rich plasma activated with 10% calcium chloride packed in a 5mL syringe will be applied to the face using a 30G needle in the frontal, lateral periorbital, nasogenian sulcus, bilateral malar region and an infra-auricular point. 0.1ml per cm2 will be injected, totaling 43 points. Only one application of PRP will be performed at the defined points.
Study NCT01106885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: * Notify PCP~* CBT Manual~* Weekly CBT focused counseling for 12 weeks\*\*~* Monthly CBT in months 4-12\*\*~* Behavioral physical activity counseling~* Report \& recommendations to PCP after each patient call~* Note: \*\*average of 50 minutes of telephone time each
Study NCT04145999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo PRP application
Description: Blood collection will be performed normally, the time between collection and application of saline will be the same as the PRP protocol, but in this case, the blood will be discarded, only a sample to quantify the number of platelets will be sent for analysis.
Study NCT04145999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation will be applied with a Cosmedical LED face mask (São Paulo, Brazil) containing 92 red LEDs. The applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP or placebo.
Study NCT02137785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid (ALA)
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Study NCT02137785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Solution Vehicle
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
Study NCT02137785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Photodynamic Therapy Illuminator (BLU-U)
Description: 10 J/cm2 blue light delivered at 10mW/cm2
Study NCT02137785 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blue Light Photodynamic Therapy Illuminator (BLU-U)
Description: 10 J/cm2 blue light delivered at 10mW/cm2
Study NCT04145999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Photobiomodulation
Description: Participants will not be aware of whether or not they have received the PBM application as they will be using eye protection and the researcher will position the equipment at the irradiation locations on all participants. The characteristic sound of the device will be triggered by recording in the placebos groups for the PBM. The placebo applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP.
Study NCT00942292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Contrast MRI scan
Study NCT03990155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNCOT+ECCO2R
Description: NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
Study NCT04454281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Hydrochloride 0.4 MG/ML
Description: Drug will be topically applied to the corneal surface then study evaluations will ensue.
Study NCT01540110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Docetaxel and Cyclophosphamide
Description: 5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)
Study NCT01874587 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adaptative radiotherapy
Description: weekly replanning
Study NCT00400868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psycho-educational Joint protection education
Description: individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
Study NCT03323372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% potassium nitrate and 0.25% sodium fluoride
Study NCT03323372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% potassium nitrate and 2% sodium fluoride
Study NCT01986049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Study NCT03668938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
Study NCT03668938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
Study NCT03668938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
Study NCT02715570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC945 - single doses
Description: Safety and tolerability of single doses
Study NCT01459913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection
Study NCT01459913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study NCT02142036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA-approved ATI based targeted therapy
Description: All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
Study NCT03766269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dronabinol
Description: Dronabinol coadministered with patient's existing Baseline Opioid.
Study NCT05746936 — intervention group
Intervention type: PROCEDURE
Intervention: Roux en-Y gastric bypass
Description: gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
Study NCT04065594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP dressing
Description: PRP dressing gel dressings for treatment of chronic ulcer
Study NCT04016376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PVB Protocol
Description: Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
Study NCT04016376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PECS-1
Description: For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
Study NCT04016376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serratus
Description: For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
Study NCT02232425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01
Study NCT02232425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06088550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BCAA
Description: a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine \& 1.25 gm valine).
Study NCT06088550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home-based graded exercise program
Description: home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
Study NCT01986049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivicaine
Study NCT01506310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
Study NCT01506310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise groups will be advised to walk at least 20-minute a day.
Study NCT01506310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral therapy and exercise
Description: General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change
Study NCT03369925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Cellulose
Study NCT03369925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline supplement
Description: Cognizin
Study NCT00665353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
Study NCT00665353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon
Description: Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
Study NCT00665353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
Study NCT04065594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional ordinary dressing
Description: conventional ordinary dressing for treatment of chronic ulcer
Study NCT00861016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol succinate prolonged-release tablet and felodipine
Description: a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
Study NCT01378429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide nasal aerosol
Description: ciclesonide nasal aerosol (74 mcg)
Study NCT01378429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02574741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Therapy
Description: Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
Study NCT02574741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: 50% of the subjects will be randomized to aripiprazole (active study medication)
Study NCT02574741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 50% of the subjects will be randomized to placebo (inactive study medication).
Study NCT01012622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
Description: OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
Study NCT02784990 — intervention group
Intervention type: BIOLOGICAL
Intervention: Lipase, amylase and CRP (C-reactive protein) dosages
Study NCT03678532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT03477799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
Study NCT03477799 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
Study NCT02334605 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cold dry air
Description: Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%.
Study NCT02334605 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hyperosmolar discs
Description: A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
Study NCT02334605 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: capsaicin nasal spray
Description: 1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
Study NCT00619489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: Vedolizumab for intravenous (IV) infusion
Study NCT01207245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin time of administration
Description: Random allocation to time of day of administration of tobramycin
Study NCT01697943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction
Study NCT04419441 — intervention group
Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: concomitant administration of radiotherapy and immune checkpoint inhibitor
Study NCT02030288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Agent Intervention
Description: Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change.
Study NCT02204852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost+eptifibatide
Study NCT02204852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01576185 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01576185 — intervention group
Intervention type: DRUG
Intervention: quizartinib
Description: Via gavage
Study NCT01576185 — intervention group
Intervention type: DRUG
Intervention: sorafenib tosylate
Description: Via gavage
Study NCT00581451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifeprunox
Description: oral tablet once daily
Study NCT04433013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lianhua Qingwen
Description: The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
Study NCT04433013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
Study NCT01188057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG
Description: A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
Study NCT01188057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Description: B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
Study NCT02704611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real tDCS
Description: Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
Study NCT02704611 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.